Study on Diacylglycerol Edible Oil's Impact on Chronic Metabolic Syndrome Patients with Hyperuricemia
A multicenter, randomized, double-blind clinical trial investigates the effects of diacylglycerol (DAG) edible oil on patients with chronic metabolic syndrome and asymptomatic hyperuricemia, comparing it with traditional triacylglycerol (TAG) oil. The study aims to evaluate the efficacy and safety of DAG oil in improving metabolic and uric acid levels over a 12-week period.
Everest Medicines' VELSIPITY® (Etrasimod) Gains Regulatory Traction in Greater China for Ulcerative Colitis Treatment
• Everest Medicines' VELSIPITY® (etrasimod) NDA has been accepted in Hong Kong for treating moderately to severely active ulcerative colitis in adults.
• VELSIPITY® has already been approved in Macau and implemented in the Greater Bay Area via the 'Hong Kong and Macau Medicine and Equipment Connect' policy.
• Clinical trials, including ELEVATE UC 52 and ELEVATE UC 12, support the efficacy and safety of etrasimod, showing significant clinical remission rates.
• Everest Medicines plans to submit an NDA to China's NMPA, aiming to extend the availability of this innovative therapy to more patients.
© Copyright 2025. All Rights Reserved by MedPath